[Databricks in GlobeNewswire] Tevogen.AI expands collaboration with Databricks and Microsoft to build the beta version of its PredicTcell™ model with a focus on oncology

WARREN, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) — Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that its artificial intelligence initiative, Tevogen.AI, is expanding its collaboration with Microsoft (Nasdaq: MSFT) and Databricks, to build the beta version of its foundational PredicTcell model.

Read more here.